While genetic factors such as SNPs in CFH may increase the likelihood of an individual to develop AMD, it is unclear if these genetic factors also underlie variations in the clinical manifestations of neovascular AMD (NVAMD) such as variable age of onset, neovascular lesion size, visual acuity, and response to therapy. Here, CFH is linked to age-related macular degeneration.